Search results
Down 67.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Clovis (CLVS)
Zacks via Yahoo Finance· 2 years agoClovis (CLVS) has become technically an oversold stock now, which implies exhaustion of the heavy...
Zacks.com featured highlights include Clovis Oncology, NiSource, DocuSign, Root and Endava
Zacks via Yahoo Finance· 1 year agoFor Immediate Release Chicago, IL – December 22, 2022 – Stocks in this week’s article are Clovis...
Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know
Zacks via Yahoo Finance· 2 years agoClovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings...
Clovis (CLVS) Stock Down 50% in the Past 6 Months: Here's Why
Zacks via Yahoo Finance· 2 years agoClovis Oncology, Inc.’s CLVS shares have plunged 49.6% in the past six months against the industry’s...
Clovis Oncology (CLVS) Reports Q2 Loss, Misses Revenue Estimates
Zacks via Yahoo Finance· 2 years agoClovis (CLVS) delivered earnings and revenue surprises of -2.38% and 15.01%, respectively, for the...
Clovis (CLVS) Q2 Loss Wider Than Expected, Revenues Miss
Zacks via Yahoo Finance· 2 years agoClovis (CLVS) incurs a wider-than-estimated loss in second-quarter 2022. Sales of the sole marketed...
Clovis (CLVS) Seeks Nod for Rubraca in First Line Ovarian Cancer
Zacks via Yahoo Finance· 2 years agoClovis (CLVS) files regulatory applications in the United States and Europe seeking label expansion...
Why Clovis Oncology Stock Is Sinking Today
Motley Fool· 2 years agoShares of the cancer drugmaker Clovis Oncology (NASDAQ: CLVS) are under pressure yet again today. After this latest dip, Clovis' stock is down by over 46% for the year. The biotech released ...
Why Clovis Oncology Stock Trounced the Market Today
Motley Fool· 2 years agoClovis Oncology (NASDAQ: CLVS) had a fine Tuesday, with its share price rising by almost 5% to beat the performance of many other biotech stocks, not to mention the S&P 500 index. A new deal ...
Why Clovis Oncology Zoomed 30% Higher Today
Motley Fool· 2 years agoCancer-focused biotech Clovis Oncology (NASDAQ: CLVS) was a stock on fire Monday. On Sunday, Clovis reported that Rubraca tested very well as a...
